Literature DB >> 19300266

Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner?

Walter R Parker1, Jeffery S Montgomery, David P Wood.   

Abstract

PURPOSE OF REVIEW: The majority of men treated for localized prostate cancer are cured of their disease. As a result, it is important to discuss long-term quality of life (QoL) expectations when counseling patients regarding treatment options. The varying QoL outcomes for radical prostatectomy, external beam radiotherapy, brachytherapy, and cryotherapy will be reviewed. RECENT
FINDINGS: Robotic and radical prostatectomy has similar outcomes with significant initial worsening of urinary continence and sexual function. External beam radiation has less impact on continence and sexual function but noteworthy bowel toxicity. Brachytherapy results in the most irritative urinary symptoms, with decreased sexual and bowel QoL as well. Cryotherapy greatly reduces sexual function.
SUMMARY: Every patient has unique pretreatment variables, priorities, and preferences. It is crucial to fully explain the range of oncologic and QoL implications when counseling patients regarding treatment for localized prostate cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19300266     DOI: 10.1097/MOU.0b013e328329eb00

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  7 in total

1.  Does the presence of robotic surgery affect demographics in patients choosing to undergo radical prostatectomy? A multi-center contemporary analysis.

Authors:  Philippa J Cheetham; Daniel J Lee; Anna Rose-Morris; Simon F Brewster; Ketan K Badani
Journal:  J Robot Surg       Date:  2010-07-10

Review 2.  [Focal therapy of prostate cancer in Germany].

Authors:  M Apfelbeck; A Herlemann; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

3.  Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer.

Authors:  M T King; R Viney; D P Smith; I Hossain; D Street; E Savage; S Fowler; M P Berry; M Stockler; P Cozzi; P Stricker; J Ward; B K Armstrong
Journal:  Br J Cancer       Date:  2012-01-24       Impact factor: 7.640

4.  TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.

Authors:  A R Azzouzi; E Barret; J Bennet; C Moore; S Taneja; G Muir; A Villers; J Coleman; C Allen; A Scherz; M Emberton
Journal:  World J Urol       Date:  2015-02-25       Impact factor: 4.226

5.  Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study.

Authors:  Cesare Selli; Anders Bjartell; Javier Burgos; Matthew Somerville; Juan-Manuel Palacios; Laure Benjamin; Libby Black; Ramiro Castro
Journal:  Prostate Cancer       Date:  2014-03-13

6.  Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients.

Authors:  Amélie Anota; Anne-Sophie Mariet; Philippe Maingon; Florence Joly; Jean-François Bosset; Anne-Valérie Guizard; Hugues Bittard; Michel Velten; Mariette Mercier
Journal:  Health Qual Life Outcomes       Date:  2016-12-06       Impact factor: 3.186

Review 7.  The primary health care physician and the cancer patient: tips and strategies for managing sexual health.

Authors:  Eric S Zhou; Larissa Nekhlyudov; Sharon L Bober
Journal:  Transl Androl Urol       Date:  2015-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.